Atara Biotherapeutics (ATRA) 10-Q2017 Q1 Quarterly report

Filed: 4 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: AAN, ahead, ALLELE, assumption, autoimmune, Boston, CA, Canada, CAT, catalyze, catastrophic, central, CHMP, CMA, CNS, cohort, collateralized, constructing, construction, covertly, daily, death, depleted, depreciated, depreciation, destroyed, dexterity, died, Dohme, donated, enhanced, equal, feasible, feet, fellow, flow, furniture, ground, GTP, half, home, honorary, HTA, incidence, inexpensively, instrument, intracellular, lab, leasehold, licensor, living, manual, median, Michael, moving, MSD, multicenter, occupancy, overexpressed, overtly, owner, pathophysiology, Pender, percent, possession, preliminary, prepaid, prepayment, protracted, readily, recede, refinement, refining, relationship, residual, restoration, revocation, secondary, Sharp, shift, software, square, suggest, survival, Thousand, tolerability, twenty, University, version, viremia

Removed: activin, Adaptimmune, Adaptive, advancing, agonist, Altor, amendment, anastrozole, antibody, applicability, Avastin, bevacizumab, biologic, Biopharma, Bioscience, body, BRCA, breast, carboplatin, cisplatin, clinic, commenced, comprised, counteract, cracked, deficiency, docetaxel, doxorubicin, draft, exemestane, exploit, explore, filanesib, gastric, gene, germline, goserelin, Helocyte, hormone, irrevocable, Karyopharm, kinesin, led, letrozole, leuprolide, liposomal, listing, misstatement, molecularly, monoclonal, muscle, mutated, myostatin, NPC, nuclear, olaparib, ovarian, paclitaxel, path, payable, peptide, prepare, prosecute, range, reliability, relying, remaining, remediate, remediated, Roche, RSA, Sanofi, Selinxor, spindle, STM, sublicense, super, superfamily, susceptibility, suspected, suspending, tamoxifen, taxane, TCR, TGF, topotecan, Transforming, transport, tyrosine, undertaken, vesting, ViraCyte

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ATRA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atara Biotherapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), Isaac Ciechanover, Chief Executive Officer of the Company, and John McGrath, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2017

/s/ Isaac Ciechanover

Isaac Ciechanover

Chief Executive Officer

(Principal Executive Officer)

/s/ John F. McGrath, Jr.

John F. McGrath, Jr.

Chief Financial Officer

(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.